Aadi Bioscience Files Proxy Materials

TL;DR

AADI filed proxy docs, no fee. Shareholders vote soon.

AI Summary

Aadi Bioscience, Inc. filed a Definitive Additional Materials proxy statement on February 5, 2025. This filing relates to the company's Schedule 14A, which is a proxy statement required under Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required for this submission.

Why It Matters

Proxy statements are crucial for shareholders as they provide information about company matters, including voting on proposals and electing directors, ensuring transparency and shareholder rights.

Risk Assessment

Risk Level: low — This filing is a routine proxy statement and does not contain information that inherently increases risk for the company or its investors.

Key Players & Entities

• Aadi Bioscience, Inc. (company) — Registrant
• 0001193125-25-020865 (filing_id) — Accession Number
• February 5, 2025 (date) — Filing Date
• Aerpio Pharmaceuticals, Inc. (company) — Former Company Name
• ZETA ACQUISITION CORP II (company) — Former Company Name

FAQ

Key Financial Figures

• $100 — Associated Infrastructure to Kaken for $100M, and $100M PIPE Financing to Support I
• $100M — Infrastructure to Kaken for $100M, and $100M PIPE Financing to Support In-Licensing
• $100 million — astructure to Kaken Pharmaceuticals for $100 million in cash; the in-licensing of a thoughtf
• $58 million — g; in 2022 and generating approximately $58 million in aggregate sales as a therapy for PEC
• $50 billion — stment capital expected to grow to over $50 billion by 2030 from some of the biggest names
• $1.8 billion — Bio until it was acquired by Genmab for $1.8 billion in May 2024. Prior to ProfoundBio, Dr.
• $43 billion — acquired by Pfizer in December 2023 for $43 billion. We believe the capital markets recog

Filing Documents

• d927047ddefa14a.htm (DEFA14A) — 36KB
• 0001193125-25-020865.txt ( ) — 37KB

Forward-Looking Statements

Forward-Looking Statements This communication contains certain forward-looking statements regarding the business of Aadi Bioscience that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Companys current beliefs and expectations and may include, but are not limited to, statements relating to: the timing and completion of the proposed sale of FYARRO to Kaken Pharmaceuticals and the anticipated timing of the closing of the transaction; expectations regarding the timing, closing and completion of the PIPE financing; Aadis expected cash position at the closing and cash runway of the Company following the sale of FYARRO and PIPE financing; the future operations of Aadi; the development and potential benefits of any of Aadis product candidates, including the preclinical ADC assets proposed to be licensed from WuXi; anticipated preclinical and clinical development activities and related timelines, including the expected timing for announcement of data and other preclinical and clinical results and potential submission of IND filings for one or more product candidates; and other statements that are not historical fact. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks associated with (i) the risk that the conditions to the closing of the proposed sale of FYARRO or the PIPE financing are not satisfied, including the failure to timely obtain stockholder approval for the transactions, if at all; (ii) uncertainties as to the timing of the consummation of the proposed transactions and the ability of each of Kaken and Aadi to consummate the proposed sale of FYARRO; (iii) risks related to Aadis ability to manage its operating expenses and its expenses associated with the proposed transactions pending the closing; (iv) risks related to th

View Full Filing

View this DEFA14A filing on SEC EDGAR